MOTS-c is a short peptide encoded not in the nuclear genome but within mitochondrial DNA, and researchers study it as a stress-responsive signal that links mitochondrial status to wider cellular metabolism. This overview examines what MOTS-c is, how the literature classifies it among mitochondrial-derived peptides, and what experimental models have and have not established.

What MOTS-c is and where it is encoded

MOTS-c — an acronym for mitochondrial open reading frame of the 12S rRNA type-c — is a 16-amino-acid peptide identified in 2015 by Lee and colleagues, who reported a short open reading frame (sORF) embedded within the mitochondrial 12S ribosomal RNA gene that encodes a bioactive signaling peptide.¹ This is an unusual origin. Most proteins that operate inside mitochondria are encoded by the nuclear genome, translated in the cytosol, and imported. MOTS-c instead arises from a coding sequence within the mitochondrial genome itself, making it a genuine product of mtDNA rather than of the nucleus.

Because it is so short and derives from a region normally annotated as ribosomal RNA rather than as a protein-coding gene, MOTS-c does not carry the classical hallmarks of a canonical protein.³ In the original characterization, the peptide was described as acting primarily on skeletal muscle, where it was reported to influence cellular one-carbon metabolism and energy sensing.¹ Its sequence is highly conserved across mammalian species, which is one reason it can be studied comparatively across rodent and human-derived cell systems.⁷ Investigators sourcing the peptide for such work — for example MOTS-C handled as a research reagent — typically prioritize sequence identity and analytical documentation, because the biology under study depends on the exact 16-residue sequence being intact.

Classifying MOTS-c within mitochondrial-derived peptides

MOTS-c does not stand alone. It is one member of a broader group called mitochondrial-derived peptides (MDPs) — small bioactive peptides translated from short open reading frames within mitochondrial ribosomal RNA genes. As of the most recent reviews, eight MDPs have been described.³ The 12S rRNA gene harbors the sequence for MOTS-c, while the 16S rRNA gene encodes the other seven: humanin and the small humanin-like peptides SHLP1 through SHLP6.³

Within this family, humanin was the first to be identified and is the most extensively studied, having been described in the context of cytoprotective and metabolic signaling. MOTS-c is distinguished by two features that recur throughout the literature: its association with the folate–AMPK energy-sensing axis, and its capacity for stress-induced nuclear translocation.²⁵ Collectively, MDPs are often framed as components of a retrograde signaling network — a communication channel by which mitochondria report their functional status back to the rest of the cell and, potentially, to distal tissues.³

Where MOTS-c sits relative to other MDPs

The reported core mechanism: folate cycle and AMPK

The mechanism most consistently attributed to MOTS-c in experimental systems runs through cellular energy sensing. In the founding study, MOTS-c was reported to inhibit the folate cycle and its tethered de novo purine biosynthesis. This interference leads to accumulation of the metabolite AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous activator of AMP-activated protein kinase (AMPK).¹ AMPK is a central regulator of cellular energy balance that responds to shifts in the AMP-to-ATP ratio under energetic challenge, and its activation is a recurring readout in MOTS-c experiments.⁶

Subsequent reviews describe this as the Folate–AICAR–AMPK pathway and treat it as the principal route through which MOTS-c is reported to influence downstream metabolic gene expression, including reported effects on transcripts such as GLUT4 in model systems.⁶ Importantly, the interaction described in models is context-dependent: MOTS-c-associated AMPK activation is reported under conditions of energetic imbalance rather than uniformly at baseline, which positions the peptide as a modulator of adaptive signaling rather than a constitutive activator.⁵⁹ Redox-linked cofactor metabolism intersects this energy-sensing biology, which is why adjacent research reagents such as NAD+ also appear in mitochondrial metabolism studies; the two are studied as distinct tools addressing different nodes of cellular energetics.

Nuclear translocation and mitonuclear communication

The feature that most sharply distinguishes MOTS-c from many other mitochondrial peptides is its reported movement into the nucleus. In 2018, Kim and colleagues showed in cell models that MOTS-c translocates to the nucleus and regulates nuclear gene expression following metabolic stress in an AMPK-dependent manner.² Under glucose restriction, nuclear MOTS-c was reported to regulate a broad set of genes, including those bearing antioxidant response elements (AREs), and to interact with stress-responsive transcription factors such as NFE2L2/NRF2.²

This finding reframed a long-standing assumption. The nuclear genome had been understood to regulate the mitochondrial genome, but MOTS-c provided evidence that a factor encoded within mtDNA could, in turn, act on nuclear gene expression — a bidirectional, genetically integrated form of mitonuclear communication.² More recent work has continued to probe how MOTS-c reaches the nucleus. A 2025 study in a rat lung ischemia-reperfusion model reported that nuclear transport of MOTS-c depended on a MYH9-associated mechanism and was accompanied by transcriptional activation of antioxidant genes such as HMOX1 and NQO1 carrying AREs.¹¹ These mechanistic details remain the subject of active investigation and are drawn from specific experimental systems rather than from human physiology.

Why localization matters experimentally

Because MOTS-c localization shifts with metabolic state, its intracellular distribution is itself an experimental variable. Under resting, nutrient-replete conditions the peptide is more cytosolic; under stress it is reported to accumulate in the nucleus.² This aligns MOTS-c more closely with conditional transcriptional regulation than with a fixed, localized mitochondrial role, and it means that stress paradigm and sampling timepoint strongly influence what a given study observes.⁵

Stress-responsive expression and metabolic flexibility

MOTS-c is best understood as inducible rather than constitutive. Reviews describe its expression rising in skeletal muscle, the systemic circulation, and even the hypothalamus in response to perturbations that stress the mitochondria — notably exercise.⁷ In human muscle, MDP expression has been reported to increase following stressors such as exercise and certain mtDNA-mutation-associated conditions, whereas circulating MDP levels tend to be lower in metabolic conditions like obesity, diabetes, and aging.³ This pattern is consistent with a tissue-level response oriented toward restoring cellular or mitochondrial homeostasis.

This behavior is often discussed through the lens of metabolic flexibility — defined in the physiology literature as the capacity of biological systems to adjust substrate utilization in response to fluctuating energetic demands, an integrated process spanning mitochondrial signaling, transcriptional control, and enzymatic regulation.⁴ The related concept of mitohormesis holds that low levels of mitochondrial stress can prompt beneficial adaptive responses, and MOTS-c is among the MDPs most closely associated with exercise-related mitohormesis in models.⁷ Upstream regulation has also been mapped: in mouse studies, adiponectin signaling through an APPL1–SIRT1–PGC-1α axis was reported to influence skeletal-muscle MOTS-c expression and its response to exercise.⁸

Cellular signaling versus systemic hormones

A common question in classification is whether MOTS-c should be treated as a hormone. Some reviews describe it in hormone-like terms because circulating levels change with physiological state.⁶ Yet its reported mode of action is grounded in intracellular signaling networks — energy sensing and nuclear transcriptional regulation — rather than in broad activation of endocrine axes.² This distinction is useful in experimental design: studying MOTS-c through cellular stress-response pathways allows metabolic adjustments to be examined with temporal and spatial precision, without invoking organism-wide hormonal cascades as the primary explanatory framework.⁵

Pharmacokinetic constraints reinforce this cellular framing. In a rodent study of a cell-penetrating MOTS-c analogue, peripherally administered native MOTS-c was reported not to cross the blood–brain barrier, prompting the use of a carrier peptide to reach the brain.¹⁰ Such findings underscore that MOTS-c behavior is tissue- and delivery-dependent, and that observations in one compartment do not automatically generalize to another.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.